Blog Posts

New dosing options for PD-1 inhibitor in first and second-line esophageal squamous cell carcinoma – BeOne Medicines

BeOne Medicines/Instagram

Apr 24, 2025, 11:06

New dosing options for PD-1 inhibitor in first and second-line esophageal squamous cell carcinoma – BeOne Medicines

BeOne Medicines shared a post on LinkedIn:

“The FDA has approved new dosing options for our PD-1 inhibitor in both first- and second-line esophageal squamous cell carcinoma (ESCC) and first-line gastric cancer, providing more flexibility for pairing our immunotherapy with the most common chemotherapy regimens.

This approval reinforces our dedication to patients in the U.S. living with upper GI cancers—helping to expand access to personalized treatment approaches and supporting providers in delivering care that fits the unique needs of each patient.”

New dosing options for PD-1 inhibitor in first and second-line esophageal squamous cell carcinoma - BeOne Medicines

BeOne Medicines cancer chemotherapy ESCC esophageal squamous cell carcinoma FDA fight against cancer GI cancers Global fight against cancer immunotherapy OncoDaily Oncology PD-1 inhibitor

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Writer?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen

Top 10 Immunotherapy Trials in Lung Cancer to Watch at ESMO 2025

FDA has Granted Full Market Approval for Papzimeos - NIH

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...